SynthesisJournal of gastroenterology2018
Systematic review with meta-analysis: real-world effectiveness and safety of vedolizumab in patients with inflammatory bowel disease.
Synthesis in Journal of gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04362735 (Efficacy of Vedolizumab in Crohn's Disease Patients Naive to Biological Therapy), which is not on this map. Cited by 96 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy of Vedolizumab in Crohn's Disease Patients Naive to Biological Therapy: a Brazilian Multicentric Observational Real-world Study
Who cites it
96 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Effectiveness and Treatment Persistence of Vedolizumab Compared to Anti-Tumour Necrosis Factor-α in Patients With Crohn's Disease: A Systematic Literature Review and Meta-Analysis.United European gastroenterology journal · 2025Pooled it
- Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review.Journal of managed care & specialty pharmacy · 2024Pooled it
- Efficacy and safety of biologics in primary sclerosing cholangitis with inflammatory bowel disease: A systematic review and meta-analysis.Hepatology communications · 2024Pooled it
- Efficacy and safety of vedolizumab for pediatrics with inflammatory bowel disease: a systematic review.BMC pediatrics · 2022Pooled it
- Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses.Journal of gastroenterology · 2020Trial
- Effectiveness of vedolizumab to reduce bowel urgency in a Canadian real-world inflammatory bowel disease cohort.Journal of the Canadian Association of Gastroenterology · 2026Article
- Inflammatory bowel disease treatment: Mechanisms to clinical translation (Review).International journal of molecular medicine · 2026Review
- Functional Gut Microbiota Alterations in Patients with Inflammatory Bowel Disease Receiving Long-Term Biologic Therapy: A Pilot Comparative Study.Journal of clinical medicine · 2026Article
- Comparative Real-World Effectiveness of Anti-TNF, Ustekinumab and Vedolizumab in Crohn's Disease Over 24 Months: A Pooled Analysis From the Prospective UMBRELLA-IBD Registry in Germany.Alimentary pharmacology & therapeutics · 2026Article
- Analysis of the use of monoclonal antibodies in the treatment of Crohn's disease.Antibody therapeutics · 2026Review
- Interleukin-23p19 Inhibitors in Inflammatory Bowel Disease: From Current Insights to Future Directions.Journal of personalized medicine · 2026Review
- Real-world data on clinical response to inflammatory bowel disease biological treatments in patients with concurrent primary sclerosing cholangitis: a case-control study.Gastroenterology report · 2026Article
- Effectiveness of vedolizumab dose escalation in inflammatory bowel disease in a large-scale, Canadian real-world cohort.Journal of the Canadian Association of Gastroenterology · 2026Article
- The UK vedolizumab real-life experience study in inflammatory bowel disease (VEST): patient characteristics, drug persistence and patient-centred outcomes.Therapeutic advances in gastroenterology · 2026Article
- A decade of clinical data with vedolizumab: the past, present, and future.Therapeutic advances in gastroenterology · 2026Review
- Long-Term Safety of Ontamalimab in Patients with Moderate to Severe Inflammatory Bowel Disease.Clinical and experimental gastroenterology · 2026Article
- Final results from the vedolizumab extended access program multinational study demonstrate long-term treatment persistence and safety.Therapeutic advances in gastroenterology · 2026Article
- Factors affecting 1-year persistence with vedolizumab for ulcerative colitis: a multicenter, retrospective real-world study.Intestinal research · 2026Article
- Association of nutritional indices with early clinical remission in patients with moderate-to-severe ulcerative colitis treated with vedolizumab.Therapeutic advances in gastroenterology · 2026Article
- MOdel-informed precision dosing (MIPD) of ustekinumab and VEdolizumab in inflammatory bowel disease: protocol for an Independent randomised, controlled, multicentre Trial (MOVE-IT).BMJ open gastroenterology · 2025Article
36 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSelective patient recruitment can produce discrepancies between clinical trial results and real-world effectiveness.
methodsA systematic literature review and meta-analysis were conducted to assess vedolizumab real-world effectiveness and safety in patients with ulcerative colitis (UC) or Crohn's disease (CD). MEDLINE, MEDLINE In-Process, EMBASE, and Cochrane databases were searched for real-world studies of vedolizumab in adult patients with UC/CD reporting clinical response, remission, corticosteroid-free remission, UC/CD-related surgery or hospitalization, mucosal healing, or safety published from May 1, 2014-June 22, 2017. Response and remission rates were combined in random-effects meta-analyses.
resultsAt treatment week 14, 32% of UC patients [95% confidence interval (CI) 27-39%] and 30% of CD patients (95% CI 25-34%) were in remission; and at month 12, 46% for UC (95% CI 37-56%) and 30% for CD (95% CI 20-42%). For UC, the rates of corticosteroid-free remission were 26% at week 14 (95% CI 20-34%) and 42% at month 12 (95% CI 31-53%); for CD they were 25% at week 14 (95%, CI 20-31%) and 31% at month 12 (95%, CI 20-45%). At month 12, 33-77% of UC and 6-63% of CD patients had mucosal healing. Nine percent of patients reported serious adverse events.
conclusionsVedolizumab demonstrated real-world effectiveness in patients with moderate-to-severely active UC or CD, with approximately one-half and one-third of patients, respectively, in remission at treatment month 12. These findings are consistent with clinical trial data and support the long-term benefit-risk profile of vedolizumab.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.